Bleeding

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Assistive technology, Conference, NASDAQ Biotechnology Index, Anticoagulant, Partnership, Metabolism, Risk, Death, Biotechnology, Warfarin, Bleeding, Antiphospholipid syndrome, APS, Atrial fibrillation, Phạm, Therapy, ESKD, Stroke, Splenic infarction, Kidney disease, Ventricular fibrillation, Patient, Apixaban, Pharmaceutical industry

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Conference, Science, Partnership, Royal college, Research and development, Bleeding, Cardiff University, Translational medicine, Trial of the century, Doctor of Philosophy, Research, Therapy, Innovation, University, Chairperson, Factor VII deficiency, Von Willebrand disease, Biogen

The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.

Key Points: 
  • The company also announced CEO Benny Sorensen, MD, PhD, will present an update on Hemab's progress and outlook for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 4:30 PM PST/7:30 PM EST.
  • We welcome Akshay and the expertise he brings to Hemab and its mission."
  • "Akshay joins our Board at a time when his experience leading translational research, clinical development and delivering regulatory success will be invaluable," said Dr. Sorensen.
  • "I am thrilled to have his partnership and to bring his passion for science and commitment to building people-focused cultures to Hemab."

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, January 3, 2024
Phase, Coagulation, Food, Emergency medicine, Risk, Vitamin K, PCC, Hemostasis, FDA, Warfarin, Bleeding, INR, Massachusetts General Hospital, Hospital, Thrombophilia, MD, Doctor of Philosophy, Factor X, Factor IX, Clinical trial, Prothrombin time, Trial of the century, Coagulation factor VII, Octapharma, VKA, Patient, Safety, Harvard Medical School, Thrombin, Pharmaceutical industry

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

Key Points: 
  • The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
  • Octapharma has the Balfaxar® production flexibility to ensure consistent supply for hospitals and medical providers.
  • "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future.
  • Balfaxar® met the primary endpoint of hemostatic efficacy in patients on a vitamin K antagonist undergoing urgent surgery with significant bleeding risk.

Global Capsule Endoscopy Market Research Report 2023: Disease Type, Product, End Use, & Region Insights and Forecasts with Potential Impact of COVID-19 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Patient, Endoscopy, Pain, Risk, Stomach, Artificial intelligence, Esophageal, Crohn's disease, Inflammatory bowel disease, Colorectal cancer, Prevalence, Bleeding, Hospital, Capsule endoscopy, COVID-19, Food, Esophagus, Growth, Diagnosis, Safety, Employment, Life, Medical imaging

The "Global Capsule Endoscopy Market (by Disease Type, Product, End Use, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Capsule Endoscopy Market (by Disease Type, Product, End Use, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global capsule endoscopy market is expected to reach US$559.59 million in 2023, growing at a CAGR of 8.64% during the forecast period.
  • The range of applications for capsule endoscopy systems, including those for colon disease, small bowel disease, and esophageal illness, has increased due to technological developments.
  • Global Capsule Endoscopy Market Players: Financial Comparison
    Global Capsule Endoscopy Market Players: R&D Expenses Comparison

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Acute coronary syndrome, Artery, European Commission, Agency, Moyamoya disease, INN, Risk, Platelet, ATC, Myocardial infarction, Bleeding, International, European, Blood, Language, Brain, Heart, Splenic infarction, Vascular disease, European Medicines Agency, Tablet, ADP, Select, Chest pain, Aspirin, Anatomy, Medicine, IIA, Atrial fibrillation, Medical device

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Estetrol, INN, Pearl, Risk, Progesterone, Woman, IIA, ATC, Bleeding, International, Headache, Ageing, Language, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised